Comparative Pharmacology
Head-to-head clinical analysis: AMITID versus IMIPRAMINE PAMOATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMITID versus IMIPRAMINE PAMOATE.
AMITID vs IMIPRAMINE PAMOATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their levels in the synaptic cleft. It also blocks histamine H1, alpha-adrenergic, and muscarinic receptors.
Imipramine is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at presynaptic neuronal membranes, increasing their concentrations in the synaptic cleft. It also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
75–150 mg orally once daily at bedtime; maximum 200 mg daily. For depression, initial dose 25–75 mg/day, titrate up to 150 mg/day. For neuropathic pain, start 10–25 mg at bedtime, increase to 25–100 mg/day.
150-300 mg orally once daily at bedtime for depression; 75-150 mg/day for panic disorder.
None Documented
None Documented
Terminal elimination half-life is 7-10 hours; clinically, steady-state is reached within 2-3 days.
11-25 hours (mean 19 h); extended in elderly (up to 30 h) and hepatic impairment; clinical context: steady-state reached in 7-14 days
Renal: 60-80% as metabolites, <5% unchanged; Biliary/Fecal: 20-30% as metabolites.
Primarily renal (70% as metabolites, <5% unchanged); 20-30% fecal via biliary excretion
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant